مباشر

Endpoints NewsLilly obesity meds Foundayo and Zepbound to gain CVS coverage BioPharma DiveGSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’Endpoints NewsFor wearables, it’s a GLP-1 world BioPharma DiveCVS obesity drug deal puts Lilly on equal footing with Novo FierceBiotechIcon ends internal accounting investigation, finds it overstated revenue in prior years FierceBiotechFDA extends Beren’s rare disease review after info request, further stretching saga BioWorldBreakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections Endpoints NewsICON audit finds overstated revenue; Secretome and Psilera raise cash Endpoints News#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project FierceBiotechHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrand CellFarnesylation-driven KRAS phase separation promotes colon tumor growth CellStructural basis of Wnt signalosome extracellular complex assembly

Endpoints News ٢٨ مايو ٢٠٢٦

Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy

Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its...

Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies are likely considering doing ...